Recent Western guidelines recommended the use of SGLT2 inhibitor in T2D patients with CKD (eGFR 30 to ≤60 mL min−1 [1.73 m]−2 or ACR >30 mg/g, particularly >300 mg/g) [132]. Here, SLC5A2 is linked to chronic kidney disease.